Signaturefd LLC Has $510,000 Position in Edwards Lifesciences Co. (NYSE:EW)

Signaturefd LLC lowered its position in Edwards Lifesciences Co. (NYSE:EW) by 19.8% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 6,685 shares of the medical research company’s stock after selling 1,652 shares during the period. Signaturefd LLC’s holdings in Edwards Lifesciences were worth $510,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Martin Capital Advisors LLP boosted its position in Edwards Lifesciences by 0.5% during the fourth quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock worth $1,944,000 after purchasing an additional 128 shares during the period. Legacy Wealth Asset Management LLC boosted its position in Edwards Lifesciences by 0.8% during the fourth quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock worth $1,293,000 after purchasing an additional 134 shares during the period. DMC Group LLC boosted its position in Edwards Lifesciences by 4.5% during the fourth quarter. DMC Group LLC now owns 3,561 shares of the medical research company’s stock worth $272,000 after purchasing an additional 154 shares during the period. Granite Harbor Advisors Inc. boosted its position in Edwards Lifesciences by 4.2% during the third quarter. Granite Harbor Advisors Inc. now owns 3,832 shares of the medical research company’s stock worth $265,000 after purchasing an additional 155 shares during the period. Finally, Stableford Capital II LLC boosted its position in Edwards Lifesciences by 2.7% during the fourth quarter. Stableford Capital II LLC now owns 5,980 shares of the medical research company’s stock worth $449,000 after purchasing an additional 155 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,715 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $90.98, for a total transaction of $156,030.70. Following the sale, the vice president now directly owns 17,213 shares of the company’s stock, valued at $1,566,038.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,715 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $90.98, for a total transaction of $156,030.70. Following the sale, the vice president now directly owns 17,213 shares of the company’s stock, valued at $1,566,038.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the sale, the chief financial officer now directly owns 19,248 shares in the company, valued at $1,506,925.92. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 194,004 shares of company stock valued at $17,166,254. 1.27% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Mizuho upped their target price on Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Royal Bank of Canada increased their price objective on Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research report on Monday, April 15th. Morgan Stanley raised their price objective on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research note on Thursday, March 21st. StockNews.com downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Wednesday, March 20th. Finally, Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research report on Thursday, March 7th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $91.73.

Edwards Lifesciences Stock Performance

NYSE EW opened at $88.62 on Thursday. The stock has a market cap of $53.34 billion, a P/E ratio of 38.53, a PEG ratio of 4.31 and a beta of 1.05. The company’s 50-day simple moving average is $90.23 and its 200 day simple moving average is $78.69. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.64. The business had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.50 billion. Edwards Lifesciences had a net margin of 23.35% and a return on equity of 23.56%. The firm’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.64 earnings per share. As a group, research analysts forecast that Edwards Lifesciences Co. will post 2.76 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.